SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?


To: Russian Bear who wrote (208)11/5/1998 5:26:00 PM
From: jayhawk969  Read Replies (1) | Respond to of 1073
 
RB,

Thanks for te edit and clarification.

J.D.



To: Russian Bear who wrote (208)11/11/1998 9:23:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 1073
 
Wednesday November 11, 4:00 am Eastern Time

Company Press Release

SOURCE: OXiGENE

OXiGENE Initiates Phase I Studies of Combretastatin

Tumor Vascular Targeting Agent Attacks Cancer-Specific Blood Vessels Formed by Angiogenesis

biz.yahoo.com